Fortive Corporation ("Fortive") today announced that James A. Lico, President and Chief Executive Officer, and Olumide Soroye, President and Chief Executive Officer of Intelligent Operating Solutions ...
Versatope Therapeutics Incorporated, a biotechnology company developing vaccines and immuno-therapeutics announced today Edward Jordan and Sam Rasty have joined the company's Board of Directors and ...
Merck said on Tuesday it has opened a $1-billion facility at its North Carolina site, the latest drugmaker to boost its U.S. manufacturing amid President Donald Trump's tariff threats.
This week's dividend activity included increased payouts from Advanced Materials (AMAT) and Dick's Sporting Goods (DKS) as ...
Regular readers will know that we love our dividends at Simply Wall St, which is why it's exciting to see Merck & Co... We recently published a list of the 11 Best Pharma Stocks to Buy According ...
Zacks Investment Research on MSN1d
Merck (MRK) Is Considered a Good Investment by Brokers: Is That True?When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about ...
During an R&D update yesterday Merck said it is hoping to claim eight new cardiovascular therapy approvals between now and 2030, for diseases like atherosclerosis, heart failure, pulmonary ...
Merck's stock dropped 1.37% in the latest session, underperforming the S&P 500’s 0.49% gain. Despite this, Merck has surged 9 ...
In October, Merck took up an option on the personalised RNA-based cancer vaccine with an upfront payment of $250 million as part of a collaboration first agreed in 2016 and expanded in 2018.
Vaccinex, Inc. (OTC: VCNX) ("Vaccinex" or the "Company"), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative ...
Derived prices are not provided by exchanges. They are derived by market makers in CFD OTC market and hence prices may not be accurate and may differ from the actual market price, meaning prices ...
Merck (NYSE:MRK) and Pfizer (NYSE:PFE) finish as the year's top gainers on the Dow Jones Industrial Average, as 14 of the 30 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback